I must admit that I closed my position and (currently) do not have any companies that develop a treatment for HBV in my portfolio.
RNAi-based compounds are simpy "too effective" in bringing down HBV RNA/DNA, i.e. too strong competition. Still, I am not sure if they are the final solution - IMHO it'd be ideal to have an compound to bring down HBsAg - the decoy/distraction to the immune systeme - while allowing some low HBV activity in cells so these cells can be identified and removed (if everything is perfectly silenced, infected and healthy cells are impossible to distinguish).
Market Data 
Markets 
AI
